A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Henan Cancer Hospital, Zhengzhou, Henan Jiangsu Province Hospital, Nanjing, Jiangsu The first hospital of Jilin University, Changchun, Jilin Liaoning Cancer Hospital, Shenyang, Liaoning Age range
18 Years and older
Last updated February 2026